
Boasting a strong market cap of $172.96 billion, Amgen Inc. (AMGN) specializes in the discovery, development, manufacturing, and distribution of human therapeutics worldwide. The company’s extensive product portfolio is dedicated to addressing diverse medical needs, spanning oncology, cardiovascular disease, and bone health.
AMGN is slated to announce its fourth quarter and full year 2023 financial results on Tuesday, February 6, 2024. Analysts project a significant 18.5% year-over-year growth for revenue to reach $8.11 billion in the fourth quarter. Similarly, the company's EPS for the same quarter is expected to climb 12.3% year-over-year to $4.59.